Jul 2026· Journal of Natural Remedies· pp. 1905-1922· 0 citations· 47 references
TL;DR
This study provides the first systems-level computational evidence for D. cinerea’s multi-target therapeutic potential in AD, establishing a molecular foundation for future experimental validation.
Abstract
Background: Alzheimer’s disease (AD) affects over 55 million individuals worldwide, and current therapies offer only symptomatic relief without modifying disease progression. The complex, multi-factorial pathology of AD — involving neuroinflammation, oxidative stress, tau hyperphosphorylation, and amyloid-β accumulation — demands a multi-target therapeutic strategy. Dichrostachys cinerea, a plant with well-documented ethnomedicinal use, presents unexplored neuroprotective potential. Aim: To investigate the multi-target anti-Alzheimer’s potential of phytochemicals derived from D. cinerea using an integrated computational approach combining GC-MS profiling, network pharmacology, molecular docking, and molecular dynamics simulation. Methods: GC-MS analysis of the hydroethanolic extract identified 134 metabolites, which were subjected to drug-likeness and ADMET screening. Network pharmacology was performed using SwissTargetPrediction and GeneCards to identify 249 common AD-related targets. PPI network analysis via STRING and CytoHubba identified hub genes. Molecular docking was carried out using AutoDock Vina against IL6 (PDB: 1ALU), GSK3β (PDB: 1Q5K), and PPARG (PDB: 6MS7). Molecular dynamics (MD) simulations were performed for 100 ns using GROMACS. Results: Among 134 identified metabolites, 92.5% exhibited favourable drug-like properties. Network analysis revealed IL6, PPARG, and GSK3β as key hub targets among 249 overlapping AD-related genes. Andrographolide demonstrated the highest binding affinities across all three targets (IL6: −8.4 kcal/mol; GSK3β: −8.8 kcal/mol; PPARG: −8.4 kcal/mol). MD simulations confirmed superior stability of the andrographolide–GSK3β complex with consistent RMSD convergence and persistent hydrogen bonding throughout 100 ns. Conclusion: This study provides the first systems-level computational evidence for D. cinerea’s multi-target therapeutic potential in AD, establishing a molecular foundation for future experimental validation.
Major Findings: Andrographolide from D. cinerea showed strong, stable binding to IL6, GSK3β, and PPARG—key AD hub targets. The andrographolide–GSK3β complex had the best docking score (−8.8 kcal/mol) and greatest MD stability over 100 ns.
Findings position SRR as a hypothesis‐generating source of multi‐target candidate molecules and provide a prioritized framework for experimental validation in AD.
Archna Singh, Avijit Mazumder, A. Kanda· ChemistrySelect· 0 citations
Tilianin is a promising dual-site AChE inhibitor candidate that may simultaneously improve cholinergic neurotransmission and reduce β-amyloid (Aβ) aggregation against AD, and further in vitro and in vivo validation studies are required to confirm its therapeutic potential.
Dini Attala Hefa Insyira, T. Tukiran· JURNAL PIJAR MIPA· 0 citations
The findings generate a testable hypothesis that QR‐PME may engage the metabolic–inflammatory–tau network connecting T2DM and AD, supporting biochemical, cellular, pharmacokinetic, and in vivo validation before its therapeutic applicability can be established.
Jean Philippe Djientcheu Tientcheu, E. Istifli· ChemistryOpen· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options offering only symptomatic relief. Natural fungal metabolites have recently gained attention for their neuroprotective potential. In this study, an extensive library of 18,349 fungal compounds was retrieved from the NPA...
Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.
Md. Mainuddin Hossain, Towfika Rahman Singdha, Saiful Islam Sakib et al.· Bioinformatics and Biology I...· 0 citations
Results from approaches examining systems and structure both indicate that ursodeoxycholic acid and tauroursodeoxycholic acid show profiles of action that work together, but they should not be interpreted as direct evidence of therapeutic efficacy in Alzheimer’s disease.
Bo Zhou, Yu Zhong, Xin Meng et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.